| Project/Area Number |
26461472
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HIRUMA Kaori 順天堂大学, 医学部, 大学院生
MATSUKI Yuko 順天堂大学, 医学部, 大学院生
KAJIWARA Mao 順天堂大学, 医学部, 実験助手
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | CTGF / 関節リウマチ / 血管新生 / 生物学的製剤 / Notch-1 / Angiogenesis / HUVEC / Rheumatoid arthritis |
|---|
| Outline of Final Research Achievements |
We found that treatment with anti-CTGF antibodies, which have been already used for clinical trials for patients with pulmonary fibrosis and are ready for clinical trial for patients with rheumatoid arthritis (RA), prevented the development of arthritis in collagen induced arthritis (CIA) mice in vivo. Moreover, we found that CTGF promoted angiogenesis to human umbilical vascular endothelial cells (HUVEC) in vitro. Although angiogenesis in one of important factors for pathogenesis of RA, biologics for direct inhibition of angiogenesis is not available for the treatment of RA. Therefore, CTGF is involved in the important therapeutic target of RA and the treatment with biologics aiming inhibition of CTGF pathway can be considered as a useful treatment of RA.
|
